FDA official recommends approval of puberty blockers despite suicide risk for gender-confused youth
According to emails, an FDA clinical team leader argued that the drugs needed to be approved so that insurance would cover them in spite of the 'increased risk of depression and suicidality, as well as increased seizure risk.'
•